A little-known advisory group to the US Food and Drug Administration will meet this week to mull over whether to ease restrictions on certain peptides. The injectables are popular among wellness influencers and some doctors, who say they improve muscle recovery, reduce inflammation, promote longevity or simply boost your overall health.
The meeting offers an early glimpse into how the second Trump administration’s drug regulators will respond to the rapidly expanding popularity of peptides that have not been FDA-approved.
The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet Thursday and Friday to review some of the controversial, popular peptide injections and discuss whether compounding pharmacies should be able to dispense them.
Previous FDA panels have largely been composed of academics and researchers. In contrast, under the second Trump administration, the current committee is made up mainly of health professionals who prescribe, produce or promote peptides.
US Health and Human Services Secretary Robert F. Kennedy Jr. has said he’s “a big fan of peptides” and has used them himself. He’s also said he hopes to relax restrictions around them but has been faced with some resistance within the FDA, which previously determined that some peptides lack sufficient safety data.
